Literature DB >> 17872671

Different conclusions about memantine.

Joel Lexchin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17872671      PMCID： PMC1949068     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


× No keyword cloud information.
  9 in total

1.  Memantine for Alzheimer's disease.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  2003-09-15       Impact factor: 1.909

2.  A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

Authors:  G Wilcock; H J Möbius; A Stöffler
Journal:  Int Clin Psychopharmacol       Date:  2002-11       Impact factor: 1.659

3.  Memantine in moderate-to-severe Alzheimer's disease.

Authors:  Barry Reisberg; Rachelle Doody; Albrecht Stöffler; Frederick Schmitt; Steven Ferris; Hans Jörg Möbius
Journal:  N Engl J Med       Date:  2003-04-03       Impact factor: 91.245

4.  Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

Authors:  B Winblad; N Poritis
Journal:  Int J Geriatr Psychiatry       Date:  1999-02       Impact factor: 3.485

Review 5.  Memantine for dementia?

Authors: 
Journal:  Drug Ther Bull       Date:  2003-10

Review 6.  [Alzheimer Disease].

Authors:  Fadi Massoud
Journal:  Can Fam Physician       Date:  2007-01       Impact factor: 3.275

7.  Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

Authors:  Jean-Marc Orgogozo; Anne-Sophie Rigaud; Albrecht Stöffler; Hans-Jorgen Möbius; Françoise Forette
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

8.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial.

Authors:  Pierre N Tariot; Martin R Farlow; George T Grossberg; Stephen M Graham; Scott McDonald; Ivan Gergel
Journal:  JAMA       Date:  2004-01-21       Impact factor: 56.272

9.  Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.

Authors: 
Journal:  Prescrire Int       Date:  2003-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.